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Background: The aims of this study were to analyze factors motivating the acceptance of interferon (IFN) therapy
and to clarify the prevalence of oral mucosal diseases in hepatitis C virus (HCV)-infected Japanese patients treated
with IFN.
Findings: A total of 94 HCV-infected patients who were admitted to our hospital for IFN therapy were asked
questions regarding their motivation to accept IFN therapy and were investigated for the presence of oral lichen
planus (OLP) before and during IFN treatment. Recommendation and encouragement from other people were the
most common factors motivating the acceptance of IFN therapy (49/94, 52.13%). The other motivators were
independent decision (30.85%), economic reasons (5.32%), and others. According to multivariate analysis, three
factors – sex (male), retreatment after previous IFN therapy, and independent decision to accept IFN therapy - were
associated with patients after curative treatment of hepatocellular carcinoma (HCC). The adjusted odds ratios for
these three factors were 26.06, 14.17, and 8.72, respectively. The most common oral mucosal lesions included OLP
in 11 cases (11.70%). One patient with OLP had postoperative squamous cell carcinoma of the tongue. The rate of
sustained virological response (SVR) was 45.45% in cases with OLP and 54.55% in cases without OLP. There were no
patients who discontinued IFN therapy because of side effects such as oral mucosal diseases.
Conclusions: We should give full explanation and recommend a course of treatment for a patient to accept IFN
therapy. The system to support liver disease as well as oral diseases is also necessary for patient treated for IFN
therapy.
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Background
Japanese hepatitis C virus (HCV)-infected patients tend
to be older than those in other countries and their older
age favors the onset of hepatocellular carcinoma (HCC),
leading to an increased mortality rate [1,2]. The number
of deaths from HCC continues to rise in Japan, where
about 80% of HCC are caused by HCV and 10% by
hepatitis B virus (HBV) [1,2].
Interferon (IFN) therapy for chronic hepatitis C is the
only treatment that enables complete elimination of the
virus. In recent years, pegylated IFN (Peg-IFN) and
ribavirin (RBV) combination therapy has been the* Correspondence: nagao@med.kurume-u.ac.jp
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distribution, and reproduction in any mediumstandard treatment for chronic hepatitis C. It has been
shown that IFN therapy contributes to the prevention
of occurrence of HCC and to improvement in long-
term prognosis [3-6]. In view of the current circum-
stances, Japan’s Ministry of Health, Labor and Welfare
introduced in April 2008 a support system for medical
costs for HCV and HBV carriers receiving IFN therapy
[7].
We reported previously factors interfering with the ac-
ceptance of IFN therapy by HCV-infected patients at
eight facilities (clinics/hospitals) [8,9]. Why is IFN ther-
apy not used more widely for treatment of HCV carriers
in Japan? Multivariate analysis demonstrated that treat-
ment facilities, sex and the presence or absence of com-
plications were factors associated with the risk that
patients would decline IFN therapy. Female patients
were more likely than male patients to decline IFNtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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the therapy.
The sustained virological response (SVR) rate after
48 weeks of Peg-IFN/RBV therapy at the standard dose
is approximately 40 to 50%, while the frequency of ad-
verse events in combination therapy with Peg-IFN/RBV
is relatively high (20-64%) [10-12]. Among the side
effects of IFN therapy, oral lesions might be easy to be
overlooked and, among the side effects in a Japanese
Phase III trial of Peg-IFN/RBV, oral mucosal disease and
dental problems have been documented in patients with
chronic hepatitis C.
HCV infection is associated with several clinical and
biological extrahepatic manifestations [13]. These in-
clude hematologic diseases such as cryoglobulinemia
and lymphoma, renal diseases such as membranoproli-
ferative glomerulonephritis, autoimmune disorders such
as thyroiditis, and dermatologic conditions such as li-
chen planus (LP) and porphyria cutanea tarda.
In the present study, we analyzed the factors motivat-
ing the acceptance of IFN therapy and investigated the
development of oral mucosal disease at the time of IFN
therapy of HCV-infected patients.Table 1 Characteristics of the 94 patients
Characteristics
Sex male / female
Age (mean± SD), years








Diagnosis of liver disease AH-C
CH-C (after HCC treatment)
LC-C (after HCC treatment)
IFN therapy IFN beta monotherapy




Peg-IFN alpha 2a monotherapy
Peg-IFN alpha 2b/RBV! Peg-IF
monotherapy
Peg-IFN alpha 2b/RBV! Peg-IF
monotherapy! Peg-IFN alpha
SD, standard deviation; AH-C, acute hepatitis C; CH-C, chronic hepatitis C; LC-C, live
pegylated interfeon; RBV, ribavirin.Methods
Patients
A total of 94 HCV-infected patients who were admitted
to the Kurume University Hospital from October 2009
to September 2011 for treatment with IFN monotherapy,
Peg-IFN monotherapy or Peg-IFN/RBV combination
therapy were studied (Table 1). All patients were admit-
ted in order to achieve sustained eradication of HCV.
Seventy-two patients had not received previous inter-
feron therapy and 22 had relapsed after previous IFN
therapy. The 94 patients were 58 men and 36 women
with a mean age of 57.01 ± 11.55 years. There were 9
patients (8 men and one woman) with histories of cura-
tive treatment for HCV-related HCC. They had been
monitored carefully for relapse over a year or more. Ex-
clusion criteria of this study were patients with long-
term maintenance IFN therapy and participants in a
clinical trial.
According to the clinical pathway, all patients had
checkups for oral mucosal diseases in the Digestive Dis-
eases Center at our Hospital. In this Digestive Diseases
Center, physicians, surgeons, radiologists and an oral























r cirrhosis type C; HCC, hepatocellular carcinoma; IFN, interferon; Peg-IFN,
Table 2 Factors motivating the acceptance of IFN therapy
Question items Multiple answers Only answer Only answer




Recommendation from a primary care doctor 62 65.96% 18 19.15% 49 52.13%
Recommendation from a hepatologist 71 75.53% 18 19.15%
With family’s encouragement 40 42.55% 8 8.51%
With the encouragemant of friends and
acquaintances
15 15.96% 4 4.26%
With encouragement from a government
office and healthcare center
2 2.13% 0 0.00%
With encouragement from a patient advocacy
group for liver disease
1 1.06% 1 1.06%
Independent decision Overcoming an illness by patient’s own
determination
79 84.04% 20 21.28% 29 30.85%
Hope of longevity for the pateint and his family 66 70.21% 9 9.57%
Economic reasons Reducing hepatitis virus-infected patient’s cost
of medical care in the Japanese medical system
from the beginning of 2008.
51 54.26% 4 4.26% 5 5.32%
Coping with lower income before the official
retirement age




Awareness of people such as family and friends
who have recovered from illness
9 9.57% 2 2.13% 5 5.32%
Awareness of death in the family and friends
having the same liver diseases
12 12.77% 3 3.19%
Increased leisure time Devotion of certain amounts of time to the
treatment of liver disease by reason of retirement
and corporate downsizing
12 12.77% 2 2.13% 3 3.19%
Devotion of certain amounts of time to the
treatment of liver disease free of elders who
need care and student taking an entrance exam
25 26.60% 0 0.00%
Coordination of work schedules to receive the treatment 34 36.17% 1 1.06%
Gathering medical
information
Participation in seminar for liver disease with patients 21 22.34% 0 0.00% 1 1.06%
Reading a newspaper, book or pamphlet 41 43.62% 0 0.00%
Watching a TV program 28 29.79% 1 1.06%
Gather information from the internet 21 22.34% 0 0.00%
Watching TV reports of lawsuits of hepatitis 23 24.47% 0 0.00%
Recovering from an
extrahepatic disease
Concentratation on the treatment of liver diseases after
recovering from an extrahepatic disease
7 7.45% 1 1.06% 1 1.06%
The others Dislike receiving injections for liver supporting therapy
thrice weekly for many months
4 4.26% 1 1.06% 1 1.06%
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the presence of oral infection before commencing IFN
treatment. All patients who received IFN therapy for
chronic HCV liver disease at our hospital were required
to undergo hospitalization for two weeks for therapeutic
management and education about liver diseases. After
the patients left the hospital, those who felt an uncom-
fortable feeling in the mouth such as reticular oral lichen
planus (OLP) and xerostomia were free to consult the
same oral surgeon. The study complied with the ethical
guidelines of the Declaration of Helsinki. Informed con-
sent was obtained from all patients after the purpose
and methods of the study were explained.Factors motivating HCV-infected patients to accept IFN
therapy
All patients answered the oral surgeon’s questions about
their motivation for accepting IFN therapy. If a physician
who treats directly chronic liver disease questions a pa-
tient, bias error occurs to patient’s answer. Therefore
oral surgeon, member of a healthcare team interviewed
to keep neutrality and equality. Specific questions based
on validation reports interfering with the acceptance of
IFN therapy by HCV-infected patients [8,9], including 1)
recommendation and encouragement from other people,
2) independent decision, 3) economic reasons, 4) out-
come of same diseases in close associates, 5) increased
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vering from an extrahepatic disease, and 8) the others,
are listed in Table 2.
Examination of oral mucosal disease
We used the headband fiber (50-100-10, Daiichi Medical
Co., Ltd.) with a brightness of 34,000 luces for mucosal
examination. Oral biopsy was performed on some
patients. The diagnosis of OLP was made on the basis of
clinical and histopathological features. Salivary flow was
measured in patients with dry mouths. We used a simple
and low-cost test for detection of xerostomia and this
required chewing on a piece of gauze for 2 min. A saliv-
ary flow rate of below 2 g/2 min was judged as
decreased salivary secretion.
Statistical analysis
All data are expressed as mean± standard error. Differ-
ences between the two groups were analyzed using Wil-
coxon’s test. Differences were judged significant for p
<0.05 (two-tailed). Adjusted odds ratios were calculated
using logistic regression analysis. All statistical analyses
were conducted using JMP Version 6 (SAS Institute,
Cary, NC, USA). The level of statistical significance was
defined as 0.05.
Results
Factors motivating why patients accepted IFN therapy
Table 2 lists multiple answers and the principal factors
motivating patients to accept IFN therapy. Of 94
patients who received IFN therapy, recommendation to
them by a physician, such as a primary care doctor or
hepatologist, family or a friend was the most common
motivation for choosing the therapy (49 cases, 52.13%).
The other motivators were: independent decision (29/94,
30.85%), economic reasons (5/94, 5.32%), outcome of
the same liver diseases in close associates (5/94, 5.32%),
increased leisure time (3/94, 3.19%), gathering medical
information (1/94, 1.06%), and recovering from an extra-
hepatic disease (1/94, 1.06%).
The principal reasons for nine patients who had previ-
ous HCC treatment accepting IFN therapy were as fol-
lows: overcoming an illness by the patient’s own
determination (4 cases), hope of longevity for the patient
and his family (2 cases), recommendation from a hepa-
tologist (2 cases), and recommendation from a primary
care doctor (1 case).
Prevalence of OLP among patients with HCV infection who
received IFN
The prevalence of OLP was 11.7% (11/94). The average
age of those with OLP (62.18 ± 6.43 years), 2 men and 9
women, was greater than that of 83 non-OLP patients
(56.33 ± 11.92 years) but there was no significantdifference. The distribution of OLP according to site of
occurrence was: buccal mucosa 11 (100%), tongue 3
(27.27%), lower lip 2 (18.18%), gingiva 1 (9.09%), oral
floor 1 (9.09%), and soft palate 1 (9.09%), among 19 sites
in 11 patients (Table 3). The erosive or reticular type of
OLP was found in 7 (63.63%) and 4 (36.36%) patients,
respectively. Onset of OLP was: before IFN therapy (8,
72.72%) and during IFN therapy (3, 27.27%). Symptoms
of three OLP patients with erosive type worsened during
IFN treatment, but those reduced their symptoms by ap-
plication of steroid. We did not need to reduce dose of
IFN and/or RBV. The effect of IFN therapy in 11 OLP
with patients were: SVR (5/11, 45.45%) and non-SVR (6/
11, 54.55%).
The other oral diseases were: postoperative squamous
cell carcinoma of the tongue (1/94, 1.06%), leukoplakia
of the tongue (1/94, 1.06%), aphthous stomatitis (3/94,
3.19%), xerostomia (3/94, 3.19%), oral candidosis (2/94,
2.12%), traumatic ulcer of the tongue (1/94, 1.06%), and
oral benign tumor (3/94, 3.19%). Two patients (2.12%)
had fissured tongue. A 57-year-old woman with OLP
had a history of resection of squamous cell carcinoma of
the tongue (T1N0M0, stage I) nine years previously.
Three patients with xerostomia had salivary flows below
the normal value (the average flow, 1.09 ± 0.07 g/2 min).
There were no patients who discontinued IFN therapy
because of side effects such as OLP and the other oral
diseases. We commenced the usual therapeutic doses of
IFN regardless of the presence of oral mucosal lesions.
Multivariate analysis of the patients with HCC after curative
treatment
According to multivariate analysis, three factors, sex
(male), retreatment after previous IFN therapy, and in-
dependent decision to accept IFN therapy, were charac-
teristic factors of the patients after curative treatment of
HCC. The adjusted odds ratios for these three factors
were 26.06, 14.17, and 8.72, respectively, and each was
statistically significant (Table 4).
Discussion
Japan has operated a universal health insurance system
since 1961. Any person who has an address in Japan
must enroll for public health insurance. Based on the in-
surance benefits, the medical fees that an individual pays
upon receiving a medical examination at a hospital, den-
tal clinic, etc. are reduced.
It is believed that between one and two million Japa-
nese people are chronically infected with HCV [1,2]. In
Japan, the Ministry of Health, Labor and Welfare alle-
viated the economic burden of therapy for diseases asso-
ciated with HCV and HBV infection in April 2008 and
expanded this system for the treatment of HBV carriers
with nucleoside analogues in April 2010 [7]. The
Table 3 Distribution of oral mucosal diseases with HCV-related liver diseases
No Sex Age Liver
disease



















type onset tongue tongue tongue
1 F 55 CH-C   erosive during IFN
therapy
2 F 58 CH-C 
3 M 54 CH-C     erosive before IFN therapy
4 M 62 CH-C   reticular during IFN
therapy
5 F 66 CH-C  erosive before IFN therapy
6 M 61 CH-C 
7 F 55 CH-C  reticular during IFN
therapy
8 F 62 CH-C  (with fissured tongue)
9 F 72 CH-C  erosive before IFN therapy
10 F 70 CH-C  (with fissured tongue)
11 M 58 CH-C 
12 F 57 CH-C    erosive before IFN therapy  (post ope.)
13 F 60 CH-C 
14 F 71 LC-C  erosive before IFN therapy 
15 F 66 CH-C 
16 M 67 CH-C 
17 F 66 CH-C 
18 F 64 CH-C   erosive before IFN therapy
19 F 61 CH-C  reticular before IFN therapy
20 F 29 CH-C 
21 F 67 CH-C  reticular before IFN therapy
22 F 49 CH-C 
23 M 48 CH-C 
CH-C: chronic hepatitis C, LC-C: HCV-related liver cirrhosis, IFN: interferon therapy, ope: operation.





















Table 4 Multivariate analysis of the patients with HCC after curative treatment
Adjusted odds ratio P
value(95% confidence interval)
Sex (male) 26.06 (3.44 - 605.65) 0.0078
Retreatment after previous IFN therapy 14.17 (2.38 - 127.99) 0.0068
Independent decision to accept IFN therapy 8.72 (1.47 - 77.00) 0.0257
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ical care in the Japanese medical system for patients
infected with hepatitis B and C viruses. Medical care cer-
tificates for receipt of IFN therapy were issued to 44,731
people from April 2008 to May 2009. The certificates
were issued to 26,594 people from April 2009 to May
2010. The certificates to receive IFN therapy and to re-
ceive nucleoside analogues therapy were issued to
28,797 and 38,038 people, respectively, from April 2010
to May 2011.
In this study, I believe we were able to collect unbiased
answers from the subjects because the oral surgeon who
questioned the patients was not involved directly with
IFN treatment. Most of the motivators for patients to re-
ceive IFN therapy were recommendation and encourage-
ment from a physician such as primary care doctor,
rather than economic reasons. Firstly patients sought to
gather information about liver disease from newspapers,
the internet, etc. Subsequently, patients finally accepted,
IFN therapy after they were satisfied with the explana-
tions from their doctor. The patients who had received
curative treatment for HCC decided for themselves to
accept IFN therapy. What should be done about the
medical approach for patients who accept IFN therapy?
Medical informed consent is essential for the physi-
cian’s ability to diagnose and treat patients, as well as
the patient’s right to accept or reject clinical evaluation,
treatment, or both [14]. Patients need to participate in
the informed consent process to understand the risk-
benefit relationship of the proposed treatment strategy.
Previously, we analyzed the factors preventing the im-
plementation of IFN therapy in terms of the one to one
relationship between the patient and primary care phys-
ician in X town (adult population: 7,389), in northern
Kyushu, Japan, where the prevalence of HCV infection is
the highest in the country [8,9]. Of 139 patients to
whom attending physicians recommended IFN therapy,
92 (66.2%) agreed to receive the treatment. In contrast,
74 (86.0%) of 86 hospital patients (treated by liver spe-
cialists) agreed to receive IFN therapy but only 18
(34.0%) of 53 clinic patients (treated by non liver-specia-
lists) did so. The difference was attributable to the inten-
sity of the effort and the strength of the explanations or
recommendations given by the physicians to the
patients. In logistic regression analysis, the adjusted odds
ratios on treatment facilities, sex and complications were18.06, 3.65, and 3.63 respectively, indicating that there
were significant differences. It is also essential to devise
measures to create cooperation between hospitals and
clinics, and to improve communication between physi-
cians and their patients.
HCV affects other organs, as well as the liver. Extrahe-
patic manifestations can be found in the mucosa, skin,
eyes, salivary gland, joints, kidneys, and immune system.
Cacoub et al. reported that 38% of patients with HCV
infection manifested at least one extrahepatic manifest-
ation [15]. We reported that the prevalence of mucous
or cutaneous LP, type 2 diabetes mellitus, hypertension,
thyroid dysfunction, and extrahepatic malignant tumor
were 19.5%, 21.8%, 28.7%, 20.7%, and 9.2%, respectively
[16]. LP is associated frequently with HCV infection and
can be exacerbated by IFN therapy. As regards the
effects of IFN therapy on LP lesions, there is a report of
their improvement [17], a report of LP manifestation
triggered by IFN [18,19], and a report of aggravation of
LP [20-23]. In long-term observation for 3 years or
longer, we reported some OLP lesions (all reticular type)
were improved, not only macroscopically but also in his-
topathologic examination [24]. The erosive type of OLP,
in particular, can cause spontaneous pain during eating
and tooth-brushing, while a patient is receiving IFN
therapy for HCV infection.
Before a patient with HCV infection receives IFN
treatment in our hospital, that patient must undergo
diagnostic evaluation of the mouth, the eyes, the mental
state and the circulatory disease. We reported that six of
570 patients could not commence IFN therapy despite
their admission, because of dental problems such as
periodontitis, pupitis, and pericoronitis [25]. Treatment
of dental infections is required before the commence-
ment of IFN therapy for HCV infection. A cooperative
system involving the various medical specialists leads to
acceptance of IFN treatment.
We have been holding regional seminars, so-called
“seminar for digestive disease”, since 2005 to improve
understanding of digestive diseases such as liver disease
and extrahepatic manifestations by patients, their fam-
ilies, and healthcare workers. A total of 3,776 people
have attended the lectures to date. It is also important
that we provide up to date knowledge of liver disease to
many people. We have to understand that various fac-
tors and motivations behind behavior, which lead to
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tween individual patients and need to support the
patients and their families by a specialist for each area
before, during, and after treatment.
Conclusions
In conclusion, we analyzed factors motivating the ac-
ceptance of IFN therapy by HCV-infected patients and
showed the importance of the effort and the strength of
the explanations or recommendations given by physi-
cians to patients. Physicians also should be aware of
OLP occurrence during IFN treatment of patients with
hepatitis C.
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